Scilex Holding Company Gain (Loss) on Extinguishment of Debt
Scilex Holding Company (SCLX) reported Gain (Loss) on Extinguishment of Debt of -$7.35 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-04-10
- Scilex Holding Company gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was -$6.25M.
- Scilex Holding Company gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- Scilex Holding Company gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- Scilex Holding Company gain (loss) on extinguishment of debt for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company gain (loss) on extinguishment of debt for fiscal 2025 was -$7.35M.
- Scilex Holding Company gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- Scilex Holding Company gain (loss) on extinguishment of debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Scilex Holding Company gain (loss) on extinguishment of debt for fiscal 2022 was $28.63M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$7.35M 10-K · filed 2026-04-10 | ||
| 2025-09-30 | -$1.10M 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $0.00 10-K · filed 2026-04-10 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $0.00 10-K · filed 2024-03-12 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2024-03-12 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $33.43M derived: sum of 4 quarters · filed 2024-03-12 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $33.43M derived: sum of 3 quarters · filed 2024-03-12 | $33.43M derived: sum of 4 quarters · filed 2024-03-12 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $33.43M derived: sum of 2 quarters · filed 2024-03-12 | $33.43M derived: sum of 3 quarters · filed 2024-03-12 | $28.63M 10-K · filed 2024-03-12 |
| 2022-09-30 | $33.43M 10-Q · filed 2023-11-14 | $33.43M derived: sum of 2 quarters · filed 2023-11-14 | $28.63M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-11 | -$4.80M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | -$4.80M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | -$12.46M 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |